TrialJournal of hematology & oncology2022

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.

Maud Toulmonde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.